← Back to Clinical Trials
Recruiting Phase 2 NCT06057675

Tranexamic Acid in Nasal Mohs Reconstruction

Trial Parameters

Condition Postoperative Bleeding
Sponsor Vanderbilt University Medical Center
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 100
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-03-19
Completion 2026-06
Interventions
Treatment (tranexamic acid and 1% lidocaine with 1:100,000 epinephrine)Control (1% lidocaine with 1:100,000 epinephrine)

Brief Summary

This study will be a prospective randomized control trial to evaluate the effects of subcutaneously administered TXA among patients undergoing nasal Mohs reconstruction with local flaps at VUMC.

Eligibility Criteria

Inclusion Criteria: 1. Adults at least 18 years of age undergoing local flap reconstruction (bilobe flap, note flap dorsal nasal flap, advancement flap) of a nasal defect following Mohs micrographic surgery. Reconstructive procedures will be performed by Drs. Yang or Patel in the division of Facial Plastic Surgery in the Department of Otolaryngology, Head and Neck Surgery at Vanderbilt University Medical Center. 2. No other facial plastic procedure or sinus surgery performed simultaneously. 3. Lack of all the below exclusion criteria. Exclusion Criteria: 1. Known allergy to TXA 2. Intracranial bleeding 3. Known defective color vision 4. History of venous or arterial thromboembolism 5. History of coagulation disorder 6. Active thromboembolic disease 7. Severe renal impairment (diagnosis of chronic kidney disease) 8. History of acute myocardial infarction 9. History of stroke 10. History of seizure 11. History of liver failure 12. Preoperative lab results indicating thrombocytopenia (pla

Related Trials